Brief: Eloxx Pharmaceuticals Announces New Development Program For ELX-02 For The Treatment Of Alport Syndrome
30/03/2022 21:22
March 30 (Reuters) - Eloxx Pharmaceuticals Inc ELOX.O :
* ELOXX PHARMACEUTICALS ANNOUNCES NEW DEVELOPMENT PROGRAM
FOR
ELX-02 FOR THE TREATMENT OF ALPORT SYNDROME
* ELOXX PHARMACEUTICALS - INITIATION OF PROOF-OF-CONCEPT
CLINICAL
TRIAL EXPECTED IN SECOND HALF OF 2022; TOPLINE RESULTS EXPECTED
IN FIRST HALF OF 2023
Source text for Eikon: ID:nGNX1GLG60
Further company coverage: ELOX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Eloxx Pharmaceuticals
See all newsNASDAQ RESUMED AT 02:24 PM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 02:19 PM
Brief: Eloxx Pharmaceuticals Provides ELX-02 And ZKN-013 Program Updates
Brief: Eloxx Pharmaceuticals Confirms That Alport Syndrome Patients Treated With Elx-02 In Phase 2 Study Had Improvement
Brief: Eloxx Pharmaceuticals Inc Reports Results In All Patients Treated With Elx-02 In Phase 2 Clinical Study For Alport Syndrome